v3.25.2
Condensed Consolidated Statements of Changes in Shareholders' Deficit - USD ($)
Common Stock [Member]
Common Class A [Member]
Common Stock [Member]
Common Class A [Member]
Parent Company [Member]
Common Stock [Member]
Common Class B [Member]
Common Stock [Member]
Common Stock [Member]
Aspire Biopharma Inc [Member]
Preferred Stock [Member]
Series A Preferred Stock [Member]
Preferred Stock [Member]
Series A Preferred Stock [Member]
Aspire Biopharma Inc [Member]
Preferred Stock [Member]
Series A Preferred Stock [Member]
Parent Company [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Aspire Biopharma Inc [Member]
Additional Paid-in Capital [Member]
Parent Company [Member]
Retained Earnings [Member]
Retained Earnings [Member]
Aspire Biopharma Inc [Member]
Retained Earnings [Member]
Parent Company [Member]
Total
Aspire Biopharma Inc [Member]
Parent Company [Member]
Balance at Dec. 31, 2022   $ 719           $ (9,938,620)     $ (9,937,901)    
Balance, shares at Dec. 31, 2022   7,187,500                        
Conversion of warrants $ 719   $ (719)                  
Conversion of warrants, shares 7,187,500   (7,187,500)                        
Reduction of U/W Fee Payable         10,812,500         10,812,500    
Contribution - shareholder non-redemption agreement         118,298         118,298    
Shareholder non-redemption agreements         (118,298)         (118,298)    
Face value of convertible note in excess of fair value         152,430         152,430    
Remeasurement for Class A shares to redemption value             (5,813,213)     (5,813,213)    
Net income (loss)             4,464,079     4,464,079 $ (359,070)  
Balance at Dec. 31, 2023 $ 719 $ 2,758 $ 22,000 10,964,930 $ 957,500 $ 976,742 (11,287,754) $ (1,467,361) $ (1,467,361) (322,105) (487,861) $ (487,861)
Balance, shares at Dec. 31, 2023 7,187,500 27,581,579 440,000,000                  
Balance at Dec. 30, 2023   $ 22,000               957,500     (1,467,361)     (487,861)
Balance, shares at Dec. 30, 2023   440,000,000                            
Retroactive application of recapitalization   $ (19,242)               19,242        
Retroactive application of recapitalization, shares   (412,418,421)                            
Balance at Dec. 31, 2023 $ 719 $ 2,758 $ 22,000 10,964,930 957,500 976,742 (11,287,754) (1,467,361) (1,467,361) (322,105) (487,861) (487,861)
Balance, shares at Dec. 31, 2023 7,187,500 27,581,579 440,000,000                  
Net income (loss)                     (230,970)     (230,970)
Issuance of common stock   $ 2               229,082         229,084
Issuance of common stock, shares   17,950                              
Balance at Mar. 31, 2024   $ 2,760               1,205,824     (1,698,331)     (489,747)
Balance, shares at Mar. 31, 2024   27,599,529                            
Balance at Dec. 31, 2023 $ 719 $ 2,758 $ 22,000 10,964,930 957,500 976,742 (11,287,754) (1,467,361) (1,467,361) (322,105) (487,861) (487,861)
Balance, shares at Dec. 31, 2023 7,187,500 27,581,579 440,000,000                  
Net income (loss)                                 (327,893)
Balance at Jun. 30, 2024   $ 2,760               1,234,385     (1,795,254)     (558,109)
Balance, shares at Jun. 30, 2024   27,601,767                            
Balance at Dec. 31, 2023 $ 719 $ 2,758 $ 22,000 10,964,930 957,500 976,742 (11,287,754) (1,467,361) (1,467,361) (322,105) (487,861) (487,861)
Balance, shares at Dec. 31, 2023 7,187,500 27,581,579 440,000,000                  
Contribution - shareholder non-redemption agreement             784,302           784,302    
Shareholder non-redemption agreements         (784,302)         (784,302)    
Face value of convertible note in excess of fair value         315,464         315,464    
Remeasurement for Class A shares to redemption value             (548,676)     (548,676)    
Net income (loss)       (12,537,472) (1,309,872)   (12,537,472) (1,309,872)  
Fair value of subscription loan - conversion option             (2,477,416)           (2,477,416)    
Issuance of common stock                        
Issuance of common stock, shares                                
Issuance of shares under working capital loans and non redemption agreements           $ 32     257,613         257,645  
Issuance of shares under working capital loans and non redemption agreements, shares           322,059                    
Balance at Dec. 31, 2024 $ 719 $ 2,760 $ 22,000 $ 32 8,802,978 1,215,113 1,234,385 (24,373,902) (2,777,233) (2,777,233) (15,570,205) (1,540,088) (1,540,088)
Balance, shares at Dec. 31, 2024 7,187,500 27,601,767 440,000,000 322,059                  
Balance at Mar. 31, 2024   $ 2,760               1,205,824     (1,698,331)     (489,747)
Balance, shares at Mar. 31, 2024   27,599,529                            
Net income (loss)                     (96,923)     (96,923)
Issuance of common stock                 28,561         28,561
Issuance of common stock, shares   2,238                              
Balance at Jun. 30, 2024   $ 2,760               1,234,385     (1,795,254)     (558,109)
Balance, shares at Jun. 30, 2024   27,601,767                            
Balance at Dec. 30, 2024   $ 22,000           $ 32     1,215,113     (2,777,233)     (1,540,088)
Balance, shares at Dec. 30, 2024   440,000,000           322,059                  
Retroactive application of recapitalization   $ (19,240)           $ (32)     19,272        
Retroactive application of recapitalization, shares   (412,398,233)           (322,059)                  
Balance at Dec. 31, 2024 $ 719 $ 2,760 $ 22,000 $ 32 8,802,978 1,215,113 1,234,385 (24,373,902) (2,777,233) (2,777,233) (15,570,205) (1,540,088) (1,540,088)
Balance, shares at Dec. 31, 2024 7,187,500 27,601,767 440,000,000 322,059                  
Conversion of warrants   $ 574               (574)        
Conversion of warrants, shares   5,735,717                              
Net income (loss)                     (15,941,328)     (15,941,328)
Issuance of shares under working capital loans and non redemption agreements   $ 554               (554)        
Issuance of shares under working capital loans and non redemption agreements, shares   5,536,946                              
Issuance of shares in Business Combination   $ 726               (4,603,302)         (4,602,576)
Issuance of shares in Business Combination, shares   7,257,513                              
Issuance of commitment fee shares under ELOC agreement   $ 110                 (110)          
Issuance of commitment fee shares under ELOC agreement, shares   1,106,527                              
Stock based compensation   $ 166                 14,131,084         14,131,250
Stock based compensation, shares   1,662,500                              
Balance at Mar. 31, 2025   $ 4,890               10,760,929     (18,718,561)     (7,952,742)
Balance, shares at Mar. 31, 2025   48,900,970                            
Balance at Dec. 31, 2024 $ 719 $ 2,760 $ 22,000 $ 32 $ 8,802,978 $ 1,215,113 1,234,385 $ (24,373,902) $ (2,777,233) (2,777,233) $ (15,570,205) $ (1,540,088) (1,540,088)
Balance, shares at Dec. 31, 2024 7,187,500 27,601,767 440,000,000 322,059                  
Net income (loss)                                 (17,922,621)
Balance at Jun. 30, 2025   $ 4,953               11,078,116     (20,699,854)     (9,616,785)
Balance, shares at Jun. 30, 2025   49,525,970                            
Balance at Mar. 31, 2025   $ 4,890               10,760,929     (18,718,561)     (7,952,742)
Balance, shares at Mar. 31, 2025   48,900,970                            
Net income (loss)                     (1,981,293)     (1,981,293)
Shares issued pursuant to debt extinguishment   $ 63               317,187         317,250
Shares issued pursuant to debt extinguishment,shares   625,000                              
Balance at Jun. 30, 2025   $ 4,953               $ 11,078,116     $ (20,699,854)     $ (9,616,785)
Balance, shares at Jun. 30, 2025   49,525,970